Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Range Study Evaluating Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccines (692342) When Administered to Healthy Adults Aged 18 to 45 Years.

NCT00621322 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00621322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00621322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Range Study Evaluating Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccines (692342) When Administered to Healthy Adults Aged 18 to 45 Years.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
April 3, 2008
Completion date
April 3, 2009
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis